Deals

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide
Auto-immuneGilead Sciences

Gilead to Acquire Oral IL‑23R Inhibitor HCXT‑2001 from PepStar Therapeutics for USD 1.275 Billion Upfront – Deepening Inflammation Pipeline with Long‑Acting Macrocyclic Peptide

Gilead Sciences, Inc. (NASDAQ: GILD) announced that it has entered into a definitive agreement with PepStar Therapeutics Limited to acquire its lead asset, HCXT‑2001, an investigational Phase I oral IL‑23…

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Yifan Pharmaceutical Signs Exclusive Commercialization Agreement With Eisai for Halaven in Mainland China – Originator Anti-Tumor Drug Strengthens Oncology Portfolio

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Astellas Pharma Partners With AI Proteins in Computational Drug Discovery Deal Worth Over USD 400 Million – Access to Miniprotein Design Platform to Strengthen Early-Stage Pipeline

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Contact US
AICancer

XtalPi and Chia Tai Tianqing Achieve Phase II Milestone in Cancer Drug Development

CAR-TCell-therapy

Overland Pharmaceuticals Partners with GoBroad Healthcare to Strengthen Cell Therapy Research

CancerFinance

Zenshine Pharmaceuticals Raises RMB 100 Million in Series B Financing for Drug Development

Chronic diseaseHKG: 1513

Livzon Pharmaceutical Secures Exclusive Rights to Onconic’s GERD Treatment Zastaprazan

Show More